Explore real-time updates from our clinical pipeline, including ongoing trial progress, patent activity, and emerging commercialization plans across global markets.
February 12, 2025
Mangoceuticals reports strong Phase 1 results showing reduced H1N1 viral load and is expanding its respiratory research to include H5N1 with a new study cohort.
Read full post
February 12, 2025
Mangoceuticals launches a new study on a water-based, non-pharma solution to help prevent avian flu in poultry using its patented antiviral tech.
Read full post
August 13, 2024
MangoRx has secured a 20-year patent grant in India for its oral-based respiratory illness prevention technology, expanding its global IP portfolio and paving the way for clinical trials and commercialization in Asia.
Read full post
July 24, 2024
MangoRx has launched pre-funded efficacy studies on its patented oral technology for preventing respiratory infections like H1N1 and avian flu, with trials led by Vipragen Biosciences in India.
Read full post
June 6, 2024
MangoRx has received patent acceptance in Australia for its oral-based respiratory illness prevention technology, expanding its global IP portfolio and paving the way for market entry and future product launches.
Read full post
June 4, 2024
MangoRx has received a Notice of Allowance in Japan for its oral-based respiratory illness prevention technology, reinforcing its global patent portfolio and paving the way for future product expansion in the region.
Read full postJoin us at leading biotech and pharma events where we share insights, present new findings, and engage with the global scientific community.
May 8, 2025
MangoRx has acquired a global patent portfolio for an oral solution targeting respiratory and oral infections, marking its entry into the non-Rx nutraceutical space with plans for both online and retail distribution.
Read full postMay 8, 2025
Mangoceuticals launches a new study on a water-based, non-pharma solution to help prevent avian flu in poultry using its patented antiviral tech.
Read full postMay 8, 2025
Mangoceuticals reports strong Phase 1 results showing reduced H1N1 viral load and is expanding its respiratory research to include H5N1 with a new study cohort.
Read full postMay 8, 2025
MangoRx has secured a 20-year patent grant in India for its oral-based respiratory illness prevention technology, expanding its global IP portfolio and paving the way for clinical trials and commercialization in Asia.
Read full postMay 8, 2025
MangoRx has launched pre-funded efficacy studies on its patented oral technology for preventing respiratory infections like H1N1 and avian flu, with trials led by Vipragen Biosciences in India.
Read full postMay 8, 2025
MangoRx has received patent acceptance in Australia for its oral-based respiratory illness prevention technology, expanding its global IP portfolio and paving the way for market entry and future product launches.
Read full postOfficial company announcements highlighting research breakthroughs, product launches, and milestone achievements shaping the future of MX-0024.
May 8, 2025
MangoRx has received a Notice of Allowance in Japan for its oral-based respiratory illness prevention technology, reinforcing its global patent portfolio and paving the way for future product expansion in the region.
Read full post
